RIP1K INHIBITORS

VE6142021000066SUndetermined Publication Date: 2022-02-17RIGEL PHARMACEUTICALS INC

View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office: VE · VE
Patent Type: Designs
Current Assignee / Owner: RIGEL PHARMACEUTICALS INC
Filing Date: 2021-03-05
Publication Date: 2022-02-17

Patent Text Reader

Need to check novelty before this filing date? Find Prior Art

Description

This document discloses kinase inhibitor compounds, such as receptor-interacting protein kinase 1 (RIP1) inhibitors, as well as pharmaceutical compositions and combinations comprising such inhibitor compounds. The disclosed compounds, pharmaceutical compositions, and / or combinations may be used to treat or prevent a kinase-related disease or condition, particularly an RIP1-related disease or condition.